<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37487596</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and systemic lupus erythematosus: A systematic review of individual patient data.</ArticleTitle><Pagination><StartPage>1164</StartPage><EndPage>1172</EndPage><MedlinePgn>1164-1172</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231191180</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Neurological involvement can occur in systemic lupus erythematosus (SLE) due to co-existing neuromyelitis optica spectrum disorder (NMOSD). The symptoms can mimic those of neuropsychiatric manifestations of SLE. Pathogenic anti-aquaporin-4 (AQP4) antibodies, commonly found in NMOSD, are responsible for the neuroinflammatory response and secondary demyelinating lesions. These anti-AQP4 antibodies can be the drivers of neuroinflammatory process in SLE patients, which is distinct from the immunopathogenesis seen in traditional neuropsychiatric SLE. The clinical course is often a relapsing one and is managed differently. In this review, we describe and outline the clinical course and outcomes of AQP4+ NMOSD/SLE overlap cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">To investigate the co-existence of SLE with AQP4+NMOSD, we conducted a systematic review of individual patient data from case reports and case series reported in major databases. The study extracted clinic-demographic features, imaging and laboratory profiles, treatment approaches, and outcomes of these patients. Inclusion criteria for the review required patients to have positivity for AQP4 or NMO in the blood and/or cerebrospinal fluid (CSF) and exhibit at least one manifestation of both NMOSD and SLE.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In this overlap between SLE and AQP4+NMOSD, a high female preponderance was observed, with 42 out of 46 patients (91.3%) being female. Nearly half of the NMOSD cases (47.8%) had onset after lupus, with a median of 5&#xa0;years between the two diagnoses. Hematological manifestations were seen in the majority of patients (63%), as well as longitudinally extensive transverse myelitis (87%), and brainstem involvement on imaging (29.6%). Cerebrospinal fluid analysis showed a dominantly lymphocytic pleocytosis, with oligoclonal bands being reported scarcely. Although cyclophosphamide was the most common steroid sparing agent used for maintenance, robust evidence for both efficacy and safety in AQP4+NMOSD is available for mycophenolate mofetil, azathioprine, and rituximab. The majority of reported cases showed a relapsing course, while one patient had a monophasic course.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">AQP4+NMOSD in SLE patients is a relapsing and neurologically disabling disorder that can mimic neuropsychiatric manifestations, frequently occurs after the onset of lupus or may predate, responds to immunosuppressants, and necessitates indefinite treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kopp</LastName><ForeName>Chirag Rajkumar</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0000-0002-2304-1361</Identifier><AffiliationInfo><Affiliation>Clinical Immunology and Rheumatology Division, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation><Identifier Source="RINGGOLD">29751</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasad</LastName><ForeName>Chandra Bhushan</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0003-1594-7873</Identifier><AffiliationInfo><Affiliation>Clinical Immunology and Rheumatology Division, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation><Identifier Source="RINGGOLD">29751</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naidu</LastName><ForeName>Shankar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Immunology and Rheumatology Division, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation><Identifier Source="RINGGOLD">29751</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Vishal</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Adult Gastroenterology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation><Identifier Source="RINGGOLD">29751</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misra</LastName><ForeName>Durga Prasanna</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.</Affiliation><Identifier Source="RINGGOLD">30093</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Vikas</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.</Affiliation><Identifier Source="RINGGOLD">30093</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Aman</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0813-1243</Identifier><AffiliationInfo><Affiliation>Clinical Immunology and Rheumatology Division, Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.</Affiliation><Identifier Source="RINGGOLD">29751</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051401">Aquaporin 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009471" MajorTopicYN="Y">Neuromyelitis Optica</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051401" MajorTopicYN="N">Aquaporin 4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Neuromyelitis optica spectrum disorder</Keyword><Keyword MajorTopicYN="N">aquaporin-4</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>24</Day><Hour>20</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37487596</ArticleId><ArticleId IdType="doi">10.1177/09612033231191180</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>